Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Wrong potency or content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk.

992 FDA drug recalls with this cause, newest first.

These recalls cover sub-potent or super-potent products, or a failed content-uniformity test - meaning some pills in the same batch held noticeably different amounts of active ingredient than others. Either way it is a direct dosing risk: too little to work, or too much and harmful. Thyroid hormones and compounded injectables are the classic examples, because their dose window is narrow.

Class III · Low risk

Nicotine polacrilex lozenge

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Terminated Wrong potency / content GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline D-1243-2014
Class III · Low risk

Nicotine polacrilex lozenge

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Terminated Wrong potency / content GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline D-1242-2014
Class III · Low risk

Nicotine polacrilex lozenge

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Terminated Wrong potency / content GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline D-1241-2014
Class III · Low risk

Nicotine polacrilex lozenge

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Terminated Wrong potency / content GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline D-1240-2014
Class III · Low risk

Nicotine polacrilex lozenge

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Terminated Wrong potency / content GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline D-1239-2014
Class III · Low risk

Nicotine polacrilex lozenge

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Terminated Wrong potency / content GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline D-1238-2014
Class III · Low risk

DermOtic Oil

Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.

Terminated Wrong potency / content Hill Dermaceuticals, Inc. NDC 28105-160-20 D-1173-2014
Class II · Moderate risk

Levothyroxine Sodium Tablets

Subpotent Drug: Assay results obtained during stability testing for Levothyroxine Sodium Tablets, USP were below specification.

Terminated Wrong potency / content Mylan Pharmaceuticals Inc. NDC 0378-1819-01 D-1084-2014
Class II · Moderate risk

Clonazepam Tablets

Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.

Terminated Wrong potency / content Actavis Elizabeth LLC NDC 0228-3005-11 D-1087-2014
Class II · Moderate risk

Irinotecan Hydrochloride Injection

Superpotent Drug: a recent review of the USP revealed that an incorrect calculation was used to determine the amount of irinotecan to use in formulation which will result in an assay higher than the labeled claim.

Terminated Wrong potency / content West-Ward Pharmaceutical Corp. NDC 0143-9701-01 D-66447-002